Portal de Periódicos da CAPES

Omeprazole and Other Proton Pump Inhibitors: Pharmacology, Efficacy, and Safety, with Special Reference to Use in Children

1998; Lippincott Williams & Wilkins; Volume: 27; Issue: 5 Linguagem: Inglês

10.1002/j.1536-4801.1998.tb01974.x

1536-4801

David M. Israel, Eric Hassall,

Pharmaceutical studies and practices

Journal of Pediatric Gastroenterology and NutritionVolume 27, Issue 5 p. 568-579 Invited Review Omeprazole and Other Proton Pump Inhibitors: Pharmacology, Efficacy, and Safety, with Special Reference to Use in Children David M. Israel, David M. Israel British Columbia Children's Hospital, Vancouver, British Columbia, CanadaSearch for more papers by this authorEric Hassall, Corresponding Author Eric Hassall n/[email protected] British Columbia Children's Hospital, Vancouver, British Columbia, CanadaAddress correspondence and reprint requests to Eric Hassall, Associate Professor, Division of Gastroenterology, B.C. Children's Hospital, 4480 Oak Street, Vancouver, British Columbia, Canada V6H3V4.Search for more papers by this author David M. Israel, David M. Israel British Columbia Children's Hospital, Vancouver, British Columbia, CanadaSearch for more papers by this authorEric Hassall, Corresponding Author Eric Hassall n/[email protected] British Columbia Children's Hospital, Vancouver, British Columbia, CanadaAddress correspondence and reprint requests to Eric Hassall, Associate Professor, Division of Gastroenterology, B.C. Children's Hospital, 4480 Oak Street, Vancouver, British Columbia, Canada V6H3V4.Search for more papers by this author First published: 01 November 1998 https://doi.org/10.1002/j.1536-4801.1998.tb01974.xRead the full textAbout ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Modlin IM. From to the Proton Pump. Schnetztor-Verlag GmbH Konstantz, Germany 1995. Google Scholar 2Hirschowitz BI. History of acid-peptic diseases: From Bismuth to Billroth to Black to Bismuth. In: Kirsner JB, ed. Philadelphia: Lea & Febiger, 1994: 54–88. Google Scholar 3Sachs G, Chang HH, Rabon E et al. A non-electrogenic H+ pump in plasma membrane of hog stomach. J Biol Chem 1976; 251: 7690–8. 10.1016/S0021-9258(17)32907-1 CASPubMedWeb of Science®Google Scholar 4Dibona DR, Ito S, Berglindh T, Sachs G. Cellular site of acid secretion. Proc Natl Acad Sci USA 1979; 76: 6689–93. 10.1073/pnas.76.12.6689 CASPubMedWeb of Science®Google Scholar 5Fellenius E, Berglindh T, Sachs G. et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking H+, K+ ATPase. Nature 1981; 290: 156–61. 10.1038/290159a0 Google Scholar 6Olbe L, Haglund U, Leth R et al. Effect of substituted benzimidazole (H149/94) on gastric acid secretion in humans. Gastroenterology 1982; 83: 193–8. 10.1016/0016-5085(82)90174-3 CASPubMedWeb of Science®Google Scholar 7Hirschowitz BI, Keeling D, Levine M, Lartigue S et al. Pharmacological aspects of acid secretion. Dig Dis Sci 1995; 40(Suppl): 3S–23S. 10.1007/BF02214869 CASPubMedWeb of Science®Google Scholar 8Bruley des Varannes S, Levy P et al. Comparison of lansoprazole and omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Alimentary Pharmacol Ther 1994; 8: 309–14. 10.1111/j.1365-2036.1994.tb00293.x CASPubMedWeb of Science®Google Scholar 9Andersson T. Pharmacokinetics of omeprazole in man. Göteborg, Sweden: Vasastadens Bokbinderi AB, 1991. Google Scholar 10Prichard P, Yeomans N, Mihaly G et al. Omeprazole: A study of its inhibition of pharmacokinetics after morning or evening dosage. Gastroenterology 1985; 88: 64–99. 10.1016/S0016-5085(85)80133-5 CASPubMedWeb of Science®Google Scholar 11Walan A, Bader JP, Classen M et al. Effect of omeprazole and ranitidine on ulcers healing and relapse rates in patients with benign gastric ulcers. N Engl J Med 1989; 320: 69–75. 10.1056/NEJM198901123200201 CASPubMedWeb of Science®Google Scholar 12Gedda K, Scott D, Besancon M et al. Turnover of the gastric H+, K+-adenosine triphosphatase alpha subunit and its effects on inhibition of rat gastric acid secretion. Gastroenterology 1995; 109: 1134–41. 10.1016/0016-5085(95)90571-5 CASPubMedWeb of Science®Google Scholar 13Peghini P, Katz P, Bedassy A et al. Nocturnal acid breakthrough during twice daily (bid) administration of proton pump inhibitor (PPI) (abstract). Gastroenterology 1997; 112: A255. PubMedWeb of Science®Google Scholar 14Freston JW. Long-term acid control and proton pump inhibitors: Interactions and safety issues in perspective. Am J Gastroenterol 1997; 92(Suppl): 51S–7S. CASPubMedWeb of Science®Google Scholar 15Freston JW, Borch K, Brand SJ et al. Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. Dig Dis Sci 1995; 40(Suppl): 50S–62S. 10.1007/BF02214871 CASPubMedGoogle Scholar 16Solcia E, Bardi C, Creutzfeldt W et al. Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1988; 41: 185–200. 10.1159/000199786 CASPubMedWeb of Science®Google Scholar 17Sachs G. The safety of omeprazole: True or false. Gastroenterology 1994; 106: 1400–1. 10.1016/0016-5085(94)90050-7 CASPubMedGoogle Scholar 18Pounder R, Smith J. Drug-induced changes of plasma gastrin concentration. Gastroenterol Clin North Am 1990; 19: 141–53. 10.1016/S0889-8553(21)00461-1 CASPubMedWeb of Science®Google Scholar 19Koop H, Naumann-Koch C, Arnold R. Effect of omeprazole on serum gastrin levels: Influence of age and sex. Gastroenterology 1990; 28: 603–5. CASGoogle Scholar 20Lamberts R, Creutzfeldt W, Striber HG et al. Long-term omeprazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth and gastritis. Gastroenterology 1993; 104: 1356–70. 10.1016/0016-5085(93)90344-C CASPubMedWeb of Science®Google Scholar 21Gunasekaran TS, Hassal E. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993; 123: 148–54. 10.1016/S0022-3476(05)81561-6 CASPubMedWeb of Science®Google Scholar 22Kato S, Ebina K, Fojii K et al. Effect of omeprazole in the treatment of refractory acid related disease in childhood: Endoscopic healing and twenty-four-hour intragastric acidity. J Pediatr 1996; 128: 415–21. 10.1016/S0022-3476(96)70293-7 CASPubMedWeb of Science®Google Scholar 23Havu N, Maoris HI, Sipponen P. Argyrophil cell hyperplasia associated with chronic corpus gastric ulcer disease. Scand J Gastroenterol 1991; 261 (Suppl): 90–2. 10.3109/00365529109103993 Google Scholar 24Ang ST, Lieberman DA, Ippoliti AF et al. Long term omeprazole therapy in patients with Barrett's esophagus is associated with parietal cell hyperplasia (abstract). Gastroenterology 1994; 106: A1016. PubMedGoogle Scholar 25Lee SW, Lieberman DA, Ippoliti AD et al. Changes in the parietal cell mass after long term therapy with high dose omeprazole in Barrett's esophagus (BE): A two year prospective study (abstract). Gastroenterology 1996; 110: A173. Google Scholar 26Weinstein WM, Ippoliti AD, Lee SW et al. Acid hypersecretion, parietal cell hyperplasia, and endoscopic changes after withdrawal of long-term high dose omeprazole therapy: A prospective study (abstract). Gastroenterology 1996; 110: A294. Web of Science®Google Scholar 27Graham JR. Gastric polyposis: Onset during long-term therapy with omeprazole. Med J Aust 1992; 157: 287–8. 10.5694/j.1326-5377.1992.tb137170.x CASPubMedWeb of Science®Google Scholar 28Weinstein WM, Ang ST, Ippoliti AF, Lieberman DA. Fundic gland polyps in patients on long term omeprazole therapy: A light and electron microscopic study of the gastric mucosa (abstract). Gastroenterology 1994; 106: A210. Web of Science®Google Scholar 29Schenk BE, Kuipers EJ, Klinkenberg-Knol EC et al. Gastric polyps during long-term omeprazole treatment for gastroesophageal reflux disease (abstract). Gastroenterology 1997; 112: A281. Web of Science®Google Scholar 30Hassall E, Dimmick JE, Israel DM. Parietal cell hyperplasia in children receiving omeprazole (abstract). Gastroenterology 1995; 108: A121. 10.1016/0016-5085(95)23148-X Google Scholar 31Israel DM, Dimmick JE, Hassall E. Gastric polyps in children on omeprazole (abstract). Gastroenterology 1995; 108: A110. 10.1016/0016-5085(95)23148-X Google Scholar 32Kuipers EJ, Uyterlinde AM, Pena AS et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: Implications for long-term safety. Am J Gastroenterol 1995; 90: 1401–6. CASPubMedWeb of Science®Google Scholar 33Kuipers EJ, Lundell L, Klinkenberg-Knol EC et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018–22. 10.1056/NEJM199604183341603 CASPubMedWeb of Science®Google Scholar 34Lundell L, Havu N, Andersson A et al. Gastritis development and acid suppression therapy revisited. Results of a randomised clinical study with long-term follow-up (abstract). Gastroenterology 1997; 112: A28. Web of Science®Google Scholar 35Schenk BE, Kuipers EJ, Klinkenberg-Knol EC et al. Atrophic gastritis during long-term omeprazole therapy is associated with decreased serum vitamin B12 levels (abstract). Gastroenterology 1997; 112: A281. Web of Science®Google Scholar 36McClay RF, Arnold R, Bardhan KD et al. Pathophysiological effects of long-term acid suppression in man. Dig Dis Sci 1995; 40: 963–1205. Google Scholar 37Koop H. Metabolic consequences of long-term inhibition of acid secretion by omeprazole. Alimentary Pharmacol Ther 1992; 6: 399–406. 10.1111/j.1365-2036.1992.tb00553.x CASPubMedWeb of Science®Google Scholar 38Jochen V, Kirkpatrick R, Greenson J et al. Fulminant hepatic failure related to omeprazole. Am J Gastroenterol 1992; 87: 523–5. PubMedGoogle Scholar 39Melville C, Shah A, Matthew D, Milla P. Electrolyte disturbance with omeprazole therapy. Eur J Pediatr 1994; 153: 49–51. CASPubMedWeb of Science®Google Scholar 40Durst RY, Pipek R, Levy Y. Hyponatremia caused by omeprazole treatment. Am J Med 1994; 97: 400–1. 10.1016/0002-9343(94)90313-1 CASPubMedWeb of Science®Google Scholar 41Singer S, Parry RG, Deodbar HA, Barnes JN. Acute interstitial nephritis: Omeprazole and antineutrophil cytoplasmic antibodies. Clin Nephrol 1994; 2: 280. Letter. Google Scholar 42Rodriguez LAG, Jick H. Risk of gynecomastia associated with cimetidine, omeprazole and antiulcer drugs. BMJ 1994; 308: 503–6. 10.1136/bmj.308.6927.503 PubMedWeb of Science®Google Scholar 43Yeomans ND, Brimblecombe RW, Elder J et al. Effect of acid suppression on microbial flora of upper gut. Dig Dis Sci 1995; 40(Suppl): 81S–95S. 10.1007/BF02214873 CASPubMedGoogle Scholar 44Oosterhuis B, Jonkman JHG. Omeprazole: Pharmacology, pharmacokinetics and interactions. Digestion 1989; 44(Suppl 1): 9–17. 10.1159/000200098 CASPubMedWeb of Science®Google Scholar 45Andersson T, Andren K, Cederberg C et al. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 1990; 39: 51–4. 10.1007/BF02657057 CASPubMedWeb of Science®Google Scholar 46Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89: 1235–41. 10.1016/0016-5085(85)90638-9 CASPubMedWeb of Science®Google Scholar 47Sutfin T, Balmer K, Gaström H et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176–84. 10.1097/00007691-198903000-00010 CASPubMedWeb of Science®Google Scholar 48Cohen AF, Kroon R, Schoemaker HX et al. Influence of gastric acidity on the bioavailability of digoxin. Ann Intern Med 1991; 115: 540–55. 10.7326/0003-4819-115-7-540 CASPubMedWeb of Science®Google Scholar 49Red T, Yem A, Cadillac M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chem Pharmacol 1993; 33: 82–4. 10.1007/BF00686028 PubMedGoogle Scholar 50Gugler R, Jensen JC. Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacal Ther 1987; 33: 133–7. 10.1016/0163-7258(87)90041-6 CASPubMedWeb of Science®Google Scholar 51Taburet AM, Geneve J, Bocquentin M et al. Theophylline steady state pharmacokinetics is not altered by omeprazole. Eur J Clin Pharm 1992; 42: 343–5. 10.1007/BF00266361 CASPubMedWeb of Science®Google Scholar 52Henry D, Brent P, Whyte I et al. Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 1987; 33: 369–73. 10.1007/BF00637632 CASPubMedWeb of Science®Google Scholar 53Blohme I, Andersson T, Idström JP. No interaction between omeprazole and cyclosporine. Br J Clin Pharmacol 1993; 35: 155–60. Google Scholar 54Chun AHC, Shi HH, Achari R et al. Lansoprazole: Administration of the contents of a capsule dosage form through a nasogastric tube. Clin Ther 1996; 5: 833–42. 10.1016/S0149-2918(96)80043-9 Google Scholar 55Sharma VK, Heinzelmann EJ, Steinberg EN et al. Non-encapsulated, intact omeprazole granules effectively suppress intragastric acidity when administered via a gastrostomy. Am J Gastroenterol 1997; 92: 848–51. CASPubMedWeb of Science®Google Scholar 56Phillips JO, Metzler MH, Palmieri TL et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996; 24: 1793–800. 10.1097/00003246-199611000-00006 CASPubMedWeb of Science®Google Scholar 57Phillips J, Metzler M. Simplified omeprazole solution for the prophylaxis of stress-related mucosal damage in critically ill patients (abstract). Crit Care Med 1994; 22: A53. 10.1097/00003246-199401000-00095 Google Scholar 58Brunner G, Chang J. Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: An open randomized controlled trial. Digestion 1990; 45: 217–25. 10.1159/000200249 CASPubMedWeb of Science®Google Scholar 59Jacqs-Aigrain E, Bellaich M, Faure C et al. Pharmacokinetics of intravenous omeprazole in children. Eur J Clin Pharmacol 1994; 47: 181–5. PubMedGoogle Scholar 60Hetzel DJ, Dent J, Reed WD et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903–12. 10.1016/0016-5085(88)90162-X CASPubMedWeb of Science®Google Scholar 61Wesdrop ICE, Dekker W, Festen HPM. Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. Dig Dis Sci 1993; 38: 2287–93. 10.1007/BF01299910 PubMedGoogle Scholar 62Armstrong D, Bennett JR, Blum AL et al. The endoscopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology 1996; 111: 85–92. 10.1053/gast.1996.v111.pm8698230 CASPubMedWeb of Science®Google Scholar 63Hassall E. Macroscopic vs. microscopic diagnosis of reflux esophagitis. Erosions or eosinophils? J Pediatr Gastroenterol Nutr 1996; 22: 321–5. 10.1002/j.1536-4801.1996.tb00096.x CASPubMedWeb of Science®Google Scholar 64Bell NJV, Burget D, Howden CW et al. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 51(Suppl 1): 59–67. 10.1159/000200917 CASPubMedWeb of Science®Google Scholar 65Orlando RC. Why is the high grade inhibition of gastric acid secretion afforded by proton pump inhibitors often required for healing of reflux esophagitis? An epithelial perspective. Am J Gastroenterol 1996; 91: 1692–6. CASPubMedWeb of Science®Google Scholar 66Champion G, Richter JE, Vaezi MF et al. Duodenogastric reflux relationship to pH and importance to Barrett's esophagus. Gastroenterology 1994; 107: 747–54. 10.1016/0016-5085(94)90123-6 CASPubMedWeb of Science®Google Scholar 67Klinkenberg-Knol EC, Jansen JMBJ, Festen HPM et al. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux esophagitis. Lancet 1987; 8529: 349–51. 10.1016/S0140-6736(87)91726-0 Google Scholar 68Dent J, Yeomans ND, Mackinnon M et al. Omeprazole v. ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trail of their efficacy and safety. Gut 1994; 35: 590–8. 10.1136/gut.35.5.590 CASPubMedWeb of Science®Google Scholar 69Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ et al. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety. Ann Intern Med 1994; 121: 161–7. 10.7326/0003-4819-121-3-199408010-00001 CASPubMedWeb of Science®Google Scholar 70Vigneri S, Termini R, Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106–10. 10.1056/NEJM199510263331703 CASPubMedWeb of Science®Google Scholar 71Smith PM, Kerr GD, Cockel R et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 1994; 107: 1312–8. 10.1016/0016-5085(94)90532-0 CASPubMedWeb of Science®Google Scholar 72Marks RD, Richter JE, Rizzo J et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907–15. 10.1016/0016-5085(94)90749-8 CASPubMedWeb of Science®Google Scholar 73Silvis SE, Farahmand M, Johnson J et al. A randomized blinded comparison of omeprazole and ranitidine in the treatment of chronic esophageal stricture secondary to acid peptic esophagitis. Gastrointest Endosc 1996; 43: 216–21. 10.1016/S0016-5107(96)70319-X CASPubMedWeb of Science®Google Scholar 74Hassall E. Wrap session: Is the Nissen slipping? Can medical treatment replace surgery for severe gastroesophageal reflux disease in children? Am J Gastroenterol 1995; 90: 1212–20. CASPubMedWeb of Science®Google Scholar 75Karjoo M, Kane R. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatro Adolesc Med 1995; 149: 267–71. 10.1001/archpedi.1995.02170150047007 CASPubMedWeb of Science®Google Scholar 76Cucchiara S, Minella R, Ierovolino C et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux esophagitis. Arch Dis Child 1993; 69: 655–9. 10.1136/adc.69.6.655 CASPubMedWeb of Science®Google Scholar 77De Giacomo C, Bawa P, Franceschi M et al. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr 1997; 24: 528–32. 10.1097/00005176-199705000-00007 CASPubMedWeb of Science®Google Scholar 78Hassall E, Israel D, Shepherd R et al. and the International Pediatric Omeprazole Study Group. Omeprazole for chronic erosive esophagitis in children: A multicenter study of dose requirements for healing (abstract). Gastroenterology 1997; 112: A143. Web of Science®Google Scholar 79Hassall E. Antireflux surgery in children: Time for a harder look. Pediatrics 1998; 101: 467–8. 10.1542/peds.101.3.467 CASPubMedWeb of Science®Google Scholar 80Heudebert GR, Marks R, Wilcox CM et al. Choice of long-term strategy for the management of patients with severe esophagitis: A cost-utility analysis. Gastroenterology 1997; 112: 1078–86. 10.1016/S0016-5085(97)70118-5 CASPubMedWeb of Science®Google Scholar 81Luostarinen M, Isolauri J, Laitinen J et al. Fate of Nissen fundoplication after 20 years. Gut 1993; 34: 1015–20. 10.1136/gut.34.8.1015 CASPubMedWeb of Science®Google Scholar 82Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582–5. CASPubMedWeb of Science®Google Scholar 83Weinstein WM, Lieberman DA, Lewin KJ et al. Omeprazole-induced regression of Barrett's esophagus: A 2 year, randomized, controlled, double-blind trial (abstract). Gastroenterology 1996; 110: A294. Web of Science®Google Scholar 84Bozymski EM, Shaheen NJ. Barrett's esophagus: Acid suppression but no regression. Am J Gastroenterol 1997; 92: 556–7. CASPubMedWeb of Science®Google Scholar 85Hassall E, Weinstein WM. Partial regression of childhood Barrett's esophagus after fundoplication. Am J Gastroenterol 1992; 87: 1506–12. CASPubMedWeb of Science®Google Scholar 86Sampliner RE, Fass R. Partial regression of Barrett's esophagus: An inadequate endpoint. Am J Gastroenterol 1993; 88: 2092–4. CASPubMedWeb of Science®Google Scholar 87Howden CW, Hornung CA. Do proton pump inhibitors induce regression of Barrett's esophagus? A systematic review (abstract). Gastroenterology 1997; 112: A152. Web of Science®Google Scholar 88Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. Am J Gastroenterol 1997; 92: 614–20. CASPubMedWeb of Science®Google Scholar 89Unge P. Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol 1996; 31: 74–81. 10.3109/00365529609094541 CASPubMedGoogle Scholar 90Sherman P, Shames B, Loo V et al. Omeprazole therapy for Helicobacter pylori infection. Scan J Gastroenterol 1992; 27: 1018–22. 10.3109/00365529209028132 CASPubMedWeb of Science®Google Scholar 91Nagata K, Takogi E, Tsunda M et al. Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: Inhibition of growth is not related to inhibition of urease. Antimicrob Agents Chemother 1995; 34: 567–70. 10.1128/AAC.39.2.567 Google Scholar 92McGowan CC, Cove TL, Blaser MJ. Helicobacter pylori and gastric acid: Biological and therapeutic implications. Gastroenterology 1996; 110: 926–38. 10.1053/gast.1996.v110.pm8608904 CASPubMedWeb of Science®Google Scholar 93McNulty CAM, Dent JC, Ford GA, Wilkinson SP. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 1988; 22: 729–38. 10.1093/jac/22.5.729 CASPubMedWeb of Science®Google Scholar 94Chey WD, Woods M, Scheiman JM et al. Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol 1997; 92: 446–50. CASPubMedWeb of Science®Google Scholar 95Labenz J, Blum AL, Bayerdorffer E et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442–7. 10.1016/S0016-5085(97)70024-6 CASPubMedWeb of Science®Google Scholar 96Labenz J, Tillenburg B, Peitz U et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997; 92: 576–81. CASPubMedWeb of Science®Google Scholar 97Schenk BE, Kuipers EJ, Klinkenberg-Knol EC et al. H. pylori, GERD and the efficacy of omeprazole therapy (abstract). Gastroenterology 1997; 112: A282. Web of Science®Google Scholar 98Gillen D, Wirz A, McColl KEL. Degree of suppression of gastric acid secretion by omeprazole is related to H. pylori status (abstracts). Gastroenterology 1997; 112: A126. Google Scholar 99Gillen D, Wirz A, McColl KEL. Marked rebound acid hypersecretion following omeprazole therapy in H. pylori negative subjects (abstract). Gastroenterology 1997; 112: A126. Google Scholar 100Bercik P, Verdu EF, Armstrong D et al. Apparent increase of acid output during omeprazole (OME) after cure of H. pylori infection (HPI) (abstract). Gastroenterology 1997; 112: A70. Web of Science®Google Scholar 101Oderda G, Dell'olio D, Morra I, Ansaldi N. Campylobacter pylori gastritis: Long term results of treatment with amoxycillin. Arch Dis Child 1989; 64: 326–9. 10.1136/adc.64.3.326 CASPubMedWeb of Science®Google Scholar 102Israel DM, Hassall E. Treatment and long term follow-up of Helicobacter pylori-associated duodenal ulcer disease in children. J Pediatr 1993; 123: 53–8. 10.1016/S0022-3476(05)81536-7 CASPubMedWeb of Science®Google Scholar 103Dohil R, Israel DM, Hassall E. Omeprazole with amoxycillin for H. pylori disease in children (abstract). Gastrointest Endosc 1995; 41: 335A. 10.1016/S0016-5107(05)80194-4 Google Scholar 104Kato S, Takeyama J, Ebina K, Naganuma H. Omeprazole-based dual and triple regimens for Helicobacter pylori in children. Pediatrics 1997; 100: 1–5. 10.1542/peds.100.1.e3 PubMedGoogle Scholar 105Dohil R, Israel DM, Hassall E. Effective two-week therapy for Helicobacter pylori disease in children. Am J Gastroenterol 1997; 92: 244–7. CASPubMedWeb of Science®Google Scholar 106Hassall E, Hiruki T, Dimmick JE. True Helicobacter-negative duodenal ulcer disease in children (abstract). Gastroenterology 1993; 104: A96. Google Scholar 107Borody TJ, George LL, Brandl S et al. Helicobacter pylori-negative duodenal ulcers. Am J Gastroenterol 1991; 86: 1154–7. CASPubMedWeb of Science®Google Scholar 108Borody TJ, Brandl S, Andrews P et al. Helicobacter pylori-negative gastric ulcer. Am J Gastroenterol 1992; 87: 1403–6. CASPubMedWeb of Science®Google Scholar 109McColl KEL, El-Nujimi AM, Chittajallu RS et al. A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 1993; 34: 762–8. 10.1136/gut.34.6.762 CASPubMedWeb of Science®Google Scholar 110Hunt R, Thompson ABR, Consensus Conference Participants. Canadian Helicobacter pylori Consensus Conference. Can J Gastroenterol 1998; 12: 31–41. 10.1155/1998/170180 CASPubMedWeb of Science®Google Scholar 111De Giacomo C, Fiocca R, Villani L et al. Omeprazole treatment of severe peptic disease associated with antral G cell hyperfunction and hyperpepsinogenemia I in an infant. J Pediatr 1990; 117: 989–93. 10.1016/S0022-3476(05)80152-0 CASPubMedGoogle Scholar 112Sontag S. Pulmonary complications of gastroesophageal reflux. In: DO Castell ed. The esophagus. Boston: Little, Brown, 1995: 555–70. Google Scholar 113Sontag SJ, O'Connell SO, Greenlee H et al. Is gastroesophageal reflux a factor in some asthmatics? Am J Gastroenterol 1987; 82: 119–26. CASPubMedWeb of Science®Google Scholar 114Meier JH, McNally PR, Punja M et al. Does omeprazole (Prilosec) improve respiratory function in asthmatics with gastro-esophageal reflux? A double-blind, placebo-controlled crossover study. Dig Dis Sci 1994; 39: 2127–33. 10.1007/BF02090360 CASPubMedWeb of Science®Google Scholar 115Waring JP, Lacayo L, Hunter J et al. Chronic cough and hoarseness in patients with severe gastroesophageal reflux disease: Diagnosis and response to therapy. Dig Dis Sci 1995; 40: 1093–7. 10.1007/BF02064205 CASPubMedWeb of Science®Google Scholar 116DeMeester TR, Bonavina L, Iascone C et al. Chronic respiratory symptoms and occult gastroesophageal reflux. A prospective clinical study and results of surgical therapy. Ann Surg 1990; 211: 337. 10.1097/00000658-199003000-00005 CASPubMedWeb of Science®Google Scholar 117Saye Z, Forget PP. Effect of cisapride on esophageal pH monitoring in children with reflux-associated bronchopulmonary disease. J Pediatr Gastroenterol Nutr 1989; 8: 327–32. 10.1002/j.1536-4801.1989.tb09762.x CASPubMedWeb of Science®Google Scholar 118Vandenplas Y, Deneyer M, Verlinden M et al. Gastroesophageal reflux incidence and respiratory dysfunction during sleep in infants: Treatment with cisapride. J Pediatr Gastroenterol Nutr 1989; 8: 31–6. 10.1002/j.1536-4801.1989.tb09697.x CASPubMedWeb of Science®Google Scholar 119Tucci F, Resti M, Fontana R et al. Gastroesophageal reflux and bronchial asthma: Prevalence and effect of cisapride therapy. J Pediatr Gastroenterol Nutr 1993; 17: 265–70. 10.1002/j.1536-4801.1993.tb10966.x CASPubMedWeb of Science®Google Scholar 120Hanson DG, Kamel PL, Kahrilas PJ. Outcome of antireflux therapy for the treatment of chronic laryngitis. Ann Otol Rhinol Laryngol 1995; 104: 550–5. 10.1177/000348949510400709 CASPubMedWeb of Science®Google Scholar 121Nishina K, Mikawa K, Maekawa N et al. Omeprazole reduces preoperative gastric fluid acidity and volume in children. Can J Anaesth 1994; 41: 925–9. 10.1007/BF03010936 CASPubMedWeb of Science®Google Scholar 122Mikawa K, Nishina K, Maekawa N et al. Lansoprazole reduces preoperative gastric fluid acidity and volume in children. Can J Anaesth 1995; 42: 467–72. 10.1007/BF03011682 CASPubMedWeb of Science®Google Scholar 123Aichbichler BW, Zerr CH, Santa Ana CA et al. Proton-pump inhibition of gastric chloride secretion in congenital chloridorrhea. N Engl J Med 1997; 336: 106–9. 10.1056/NEJM199701093360205 CASPubMedWeb of Science®Google Scholar 124Zech K, Steinijans, VW, Huber R et al. Pharmacokinetics and drug interactions: Relevant factors for the choice of a drug. Int J Clin Pharmacol Ther 1996; 34(Suppl 1): 53–6. CASGoogle Scholar 125Beker JA. Bianchi Porro G, Bigard M-A, et al. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7: 407–10. CASPubMedWeb of Science®Google Scholar 126Castell DO, Richter JE, Robinson M et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. Am J Gastroenterol 1996; 91: 1749–57. CASPubMedWeb of Science®Google Scholar 127Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg versus 40 mg omeprazole in the treatment of reflux esophagitis grade II, III, and IV (a Dutch multicentre trial). Eur J Gastroenterol Hepatol 1996; 8: 1101–6. 10.1097/00042737-199611000-00013 CASPubMedWeb of Science®Google Scholar 128Sontag SJ, Kogut DG, Fleischman R et al. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Am J Gastroenterol 1997; 92: 429–37. CASPubMedWeb of Science®Google Scholar 129Jaspersen D, Diehl KL, Geyer P et al. Omeprazole is superior to lansoprazole and pantoprazole for maintenance treatment of complicated reflux esophagitis (abstract). Gastroenterology 1997; 112: A159. Google Scholar Volume27, Issue5November 1998Pages 568-579 ReferencesRelatedInformation